Zogenix (ZGNX) Upgraded to “Buy” by BidaskClub
Zogenix (NASDAQ:ZGNX) was upgraded by stock analysts at BidaskClub from a “hold” rating to a “buy” rating in a research note issued to investors on Saturday.
Other research analysts have also recently issued research reports about the company. Mizuho reiterated a “buy” rating and set a $51.00 price objective on shares of Zogenix in a research report on Wednesday, November 8th. JMP Securities initiated coverage on Zogenix in a research report on Monday, November 27th. They set an “outperform” rating and a $56.00 price objective on the stock. Zacks Investment Research upgraded Zogenix from a “sell” rating to a “hold” rating in a research report on Saturday, January 27th. Finally, ValuEngine upgraded Zogenix from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Two equities research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. Zogenix currently has an average rating of “Buy” and a consensus price target of $42.67.
Shares of Zogenix (NASDAQ ZGNX) opened at $37.75 on Friday. Zogenix has a twelve month low of $8.50 and a twelve month high of $43.35. The stock has a market capitalization of $1,293.01, a price-to-earnings ratio of -8.54 and a beta of 1.79. The company has a current ratio of 2.71, a quick ratio of 2.71 and a debt-to-equity ratio of 0.23.
A number of hedge funds have recently bought and sold shares of ZGNX. American International Group Inc. increased its position in shares of Zogenix by 38.7% in the fourth quarter. American International Group Inc. now owns 23,057 shares of the company’s stock worth $923,000 after purchasing an additional 6,434 shares during the period. Vivo Capital LLC bought a new position in shares of Zogenix in the fourth quarter worth $4,205,000. Virtu Financial LLC bought a new position in shares of Zogenix in the fourth quarter worth $683,000. BlackRock Inc. increased its position in shares of Zogenix by 30.6% in the fourth quarter. BlackRock Inc. now owns 2,656,444 shares of the company’s stock worth $106,389,000 after purchasing an additional 622,668 shares during the period. Finally, Bank of New York Mellon Corp increased its position in shares of Zogenix by 28.5% in the fourth quarter. Bank of New York Mellon Corp now owns 170,627 shares of the company’s stock worth $6,834,000 after purchasing an additional 37,821 shares during the period. Hedge funds and other institutional investors own 73.54% of the company’s stock.
Zogenix Company Profile
Zogenix, Inc is a pharmaceutical company engaged in developing and commercializing central nervous system (CNS) therapies that address specific clinical needs for people living with orphan and other CNS disorders. Its primary area of therapeutic focus is epilepsy and related seizure disorders. Its lead product candidate, ZX008, is a low-dose fenfluramine for the treatment of seizures associated with Dravet syndrome.
Receive News & Ratings for Zogenix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zogenix and related companies with MarketBeat.com's FREE daily email newsletter.